<?xml version="1.0" encoding="UTF-8"?>
<p>The potential benefits of PVI as well as topical immunosuppressive therapies gave rise to the development of combined PVI/steroid ophthalmic solutions. The idea of combining these elements is to employ the antiseptic properties of PVI in conjunction with symptomatic relief of inflammation, with the added benefit of reducing the risk and/or treatment of SEI formation and scarring.
 <xref rid="CIT0002" ref-type="bibr">2</xref>,
 <xref rid="CIT0052" ref-type="bibr">52</xref>,
 <xref rid="CIT0072" ref-type="bibr">72</xref>,
 <xref rid="CIT0091" ref-type="bibr">91</xref> Initial efficacy of combo PVI 0.4%/dexamethasone 0.1% dosed QID for five days was evaluated in a small study of nine eyes utilizing Rapid Pathogen Screening Adeno Detector-positive acute viral conjunctivitis.
 <xref rid="CIT0091" ref-type="bibr">91</xref> The pilot study included both clinical (conjunctival injection and discharge) and serological (reduction of quantitative polymerase chain reaction titers and eradication of infectious virus as determined by cell culture with confirmatory immunofluorescence) endpoints.
 <xref rid="CIT0091" ref-type="bibr">91</xref>
</p>
